Clinical Trial Update: Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gemcitabine/carboplatin with or without the PARP1 inhibitor in untreated stage IV squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Iniparib (iparib)

Snippet

Sponsor: Sanofi | Conditions: Squamous Cell Lung Cancer | Phase 3 | Status: COMPLETED